Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Smith & Nephew posts sharp rise in profit and cash flow
Smith+Nephew reported a strong finish to 2025, with profits and cash flow rising as it completed its three-year turnaround plan and set out ambitions for faster growth. Fourth quarter revenue rose 8.3% to $1.7 billion, or 6.2% on an underlying basis, meaning full-year revenue increased 6.1% to $6.2 billion, with underlying growth of 5.3%.
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across its divisions.
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal
SNN expands its Sports Medicine portfolio with Integrity Orthopaedics, adding next-gen Tendon Seam tech to strengthen leadership in shoulder repair.
Smith & Nephew: Improving And Undervalued, But Mind The Knees
Smith & Nephew has outperformed peers, driven by strong sports medicine and wound care, despite ongoing ortho business challenges. SNN's major joints segment remains a sore spot, with ongoing underperformance in knees and threats from Stryker's increased focus on ASCs. Management's 6–7% annualized growth guidance through 2028 is ambitious; I expect 5%+ growth with 2-3 points of adjusted EBITDA margin improvement.
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript
Smith & Nephew plc ( SNN ) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets, Research Division Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Graham Doyle - UBS Investment Bank, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division Julien Dormois - Jefferies LLC, Research Division David Adlington - JPMorgan Chase & Co, Research Division Presentation Operator Good morning. Thank you for attending today's Smith & Nephew Quarter 3 2025 Trading Report.
Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release
Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis point trading margin expansion support management's confidence in achieving full-year guidance. Technical analysis reveals significant resistance at $38 and $40-$42, with bearish intermediate signals suggesting potential price weakness over the next 6-10 months.
SNN or SYK: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
SNN vs. SYK: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
Smith & Nephew: Doing Better And Still Offers Value
Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, and a $500m buyback signals management's confidence in cash generation, though yield remains modest. The company's recovery is gaining traction, even if ambitious margin targets remain unmet; momentum is building across all business units and regions.
